

# Ahmet Emre EÅkazan

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2187799/publications.pdf>

Version: 2024-02-01

159  
papers

1,173  
citations

430442

18  
h-index

552369

26  
g-index

159  
all docs

159  
docs citations

159  
times ranked

1597  
citing authors

#	ARTICLE	IF	CITATIONS
1	<sup>18</sup> F-Fluorodeoxyglucose Positron Emission Tomography/Magnetic Resonance Imaging Appearance of Gastrointestinal Behçet's Disease. <i>Molecular Imaging and Radionuclide Therapy</i> , 2022, 31, 57-59.	0.3	1
2	Gilteritinib in the management of acute myeloid leukemia: Current evidence and future directions. <i>Leukemia Research</i> , 2022, 114, 106808.	0.4	10
3	Spotlight Commentary "Voxelotor: A new kid on the block in the treatment of sickle cell disease. <i>British Journal of Clinical Pharmacology</i> , 2022, 88, 2564-2565.	1.1	1
4	Patient characteristics and management practices in chronic myeloid leukemia in Turkey: reflections from an expert meeting. <i>Expert Review of Hematology</i> , 2022, 15, 97-106.	1.0	4
5	Tackling TKI resistance in AML: A commentary on "Inhibition of BCL2A1 by STAT5 inactivation overcomes resistance to targeted therapies of FLT3-ITD/D835 mutant AML." by Yamatani et al.. <i>Translational Oncology</i> , 2022, 19, 101394.	1.7	0
6	Is it possible to predict the pCR with CBC? A commentary on "correlation analysis of lymphocyte-monocyte ratio with pathological complete response and clinical prognosis of neoadjuvant chemotherapy in patients with breast cancer" by Meng et al.. <i>Translational Oncology</i> , 2022, 20, 101403.	1.7	0
7	Management of chronic myeloid leukemia in myeloid blastic phase with novel therapies: a systematic literature review. <i>Expert Review of Hematology</i> , 2022, 15, 423-429.	1.0	3
8	A new dawn for upfront autologous SCT in NK/T-cell lymphomas: One more step forward in reasoning. <i>International Journal of Cancer</i> , 2022, 151, 661-664.	2.3	0
9	COVID-19 presenting with immune thrombocytopenia: A case report and review of the literature. <i>Journal of Medical Virology</i> , 2021, 93, 43-45.	2.5	41
10	Platelet count threshold for lumbar puncture: Does one size really fit all?. <i>Transfusion</i> , 2021, 61, 329-329.	0.8	0
11	The prognostic value of serum levels of a proliferation-inducing ligand (APRIL) in treatment-naïve patients with chronic lymphocytic leukemia. <i>Turkish Journal of Medical Sciences</i> , 2021, 51, 348-354.	0.4	0
12	What is the best treatment approach for sporadic late-onset nemaline myopathy associated with "monoclonal gammopathy of neurological significance"? <i>International Journal of Cancer</i> , 2021, 148, 2638-2639.	2.3	2
13	COVID-19 in Chronic-Phase Chronic Myeloid Leukemia Patients: A Single-Center Survey from Turkey. <i>Turkish Journal of Haematology</i> , 2021, 38, 79-81.	0.2	11
14	Asciminib in chronic myeloid leukemia: many questions still remain to be answered. <i>Blood Cancer Journal</i> , 2021, 11, 81.	2.8	4
15	KRONİK LENFOSİTİK Lİ-MEMO TANILI HASTALARDA KİLLER İMMÜNÜGLOBULİN LİKE RESEPTÖR GEN DEĞERLERİNİN OTOİMMÜN OLAYLAR İLE İLİŞKİSİ. İstanbul Tıp Fakültesi Dergisi, 2021, 84, .	0.1	0
16	Candida esophagitis incidentally detected by 18F-FDG PET/CT in a patient with CNS lymphoma. <i>Clinical Case Reports (discontinued)</i> , 2021, 9, e04322.	0.2	3
17	A clinical appraisal of chronic myeloid leukaemia (CML)-related death and CML-specific death "Are they synonymous?. <i>International Journal of Clinical Practice</i> , 2021, 75, e14217.	0.8	1
18	Ponatinib both as an effective bridge to allogeneic hematopoietic stem cell transplantation and as posttransplant maintenance therapy in a chronic myeloid leukemia patient with myeloid blast crisis. <i>Hematology, Transfusion and Cell Therapy</i> , 2021, , .	0.1	0

#	ARTICLE	IF	CITATIONS
19	Do patients with immune-mediated thrombotic thrombocytopenic purpura receiving caplacizumab need antithrombotic therapy?. <i>Expert Review of Clinical Pharmacology</i> , 2021, 14, 1183-1188.	1.3	9
20	New kid on the block: C-reactive protein-to-albumin ratio as a new prognostic marker for chronic lymphocytic leukemia: Comment on "C-reactive protein-to-albumin ratio is an independent poor prognostic factor in newly diagnosed chronic lymphocytic leukaemia: A clinical analysis of 322 cases" Translational Oncology, 2021, 14, 101098.	1.7	1
21	Efficacy and Safety of Imatinib Treatment in Elderly Patients With Chronic Myeloid Leukemia: Real-Life Data and a Single-Center Experience. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, 21, 549-557.	0.2	4
22	Tocilizumab in COVID-19: The CerrahpaÅYa-PREDICT score. <i>Journal of Infection and Chemotherapy</i> , 2021, 27, 1329-1335.	0.8	9
23	Current evidence on the efficacy and safety of generic imatinib in CML and the impact of generics on health care costs. <i>Blood Advances</i> , 2021, 5, 3344-3353.	2.5	16
24	Intracranial hemorrhage in immune thrombotic thrombocytopenic purpura treated with caplacizumab: COMMENT from EYkazan et al. <i>Journal of Thrombosis and Haemostasis</i> , 2021, 19, 2644-2646.	1.9	1
25	Bosutinib " related pleural effusion in patients with chronic myeloid leukemia. <i>Expert Opinion on Drug Safety</i> , 2021, 20, 379-381.	1.0	5
26	Novel <i>BCR-ABL1</i> tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia. <i>Expert Review of Hematology</i> , 2021, 14, 975-978.	1.0	14
27	Giant Cell Arteritis with Concomitant Chronic Myelomonocytic Leukemia. <i>Turkish Journal of Haematology</i> , 2021, 38, 226-227.	0.2	0
28	The Impact of the COVID-19 Pandemic on the Diagnosis and Management of Patients with Classical Hodgkin Lymphoma: A Single-Center Experience. <i>Blood</i> , 2021, 138, 1394-1394.	0.6	0
29	Treatment Responses, Toxicity and Survival in Patients with Classical Hodgkin Lymphoma Aged 50 Years and Older: A Single-Center Experience over 2 Decades. <i>Blood</i> , 2021, 138, 4541-4541.	0.6	0
30	The Impact of EUTOS Long-Term Survival (ELTS) Score on Predicting Progression and Survival Among Turkish Patients with Chronic Myeloid Leukemia. <i>Blood</i> , 2021, 138, 4600-4600.	0.6	0
31	Asciminib as a new option in the treatment of chronic myeloid leukemia. <i>Future Oncology</i> , 2021, 17, 5003-5005.	1.1	6
32	The Impact and Prognostic Significance of Chronic Lymphocytic Leukemia Upregulated 1 (CLLU1) Gene Expression in Patients with Chronic Lymphocytic Leukemia: A Single Center Experience. <i>Laboratory Medicine</i> , 2020, 51, 259-264.	0.8	1
33	Replacing chemotherapy with arsenic trioxide for the treatment of acute promyelocytic leukemia in the frontline setting: Is it cost-effective?. <i>Cancer</i> , 2020, 126, 256-259.	2.0	1
34	&lt;p&gt;Assessment and Monitoring of Patients with Immune-Mediated Thrombotic Thrombocytopenic Purpura (iTTP): Strategies to Improve Outcomes&lt;/p&gt;. <i>Journal of Blood Medicine</i> , 2020, Volume 11, 319-326.	0.7	10
35	Hepatitis B reactivation in hematopoietic stem cell transplanted patients: 20 years of experience of a single center from a middle endemic country. <i>Annals of Hematology</i> , 2020, 99, 2671-2677.	0.8	5
36	Copy-number variations in adult patients with chronic immune thrombocytopenia. <i>Expert Review of Hematology</i> , 2020, 13, 1277-1287.	1.0	3

#	ARTICLE	IF	CITATIONS
37	Moving on from 2013 to 2020 European LeukemiaNet recommendations for treating chronic myeloid leukemia: what has changed over the 7 years?. <i>Expert Review of Hematology</i> , 2020, 13, 1035-1038.	1.0	11
38	Therapy-related chronic myeloid leukemia in a patient receiving peptide receptor radionuclide therapy for pancreatic neuroendocrine tumor. <i>Cancer Reports</i> , 2020, 3, e1282.	0.6	3
39	Chronic myeloid leukaemia and the use of tyrosine kinase inhibitors in the days of COVID-19 pandemic. <i>British Journal of Clinical Pharmacology</i> , 2020, 86, 1790-1792.	1.1	5
40	Management of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Chronic Myeloid Leukemia: What is the Best Strategy?. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, e237-e238.	2.0	0
41	Is it beneficial to use hydroxychloroquine and imatinib combination in order to achieve deeper molecular responses in patients with chronic myeloid leukemia?. <i>Leukemia</i> , 2020, 34, 3426-3427.	3.3	2
42	Novel therapeutic approaches in chronic myeloid leukemia. <i>Leukemia Research</i> , 2020, 91, 106337.	0.4	33
43	Bosutinib "an effective and safe treatment option in the management of chronic myeloid leukemia. <i>Future Oncology</i> , 2020, 16, 4425-4428.	1.1	3
44	Follicular lymphoma generating in a patient with non-small cell lung cancer following nivolumab discontinuation. <i>Journal of Oncology Pharmacy Practice</i> , 2020, 26, 2042-2046.	0.5	2
45	Idasanutlin as a new treatment option in improving the therapeutic odyssey of relapsed/refractory AML. <i>Future Oncology</i> , 2020, 16, 887-889.	1.1	0
46	Deep sequencing of <i>BCR-ABL1</i> kinase domain mutations in chronic myeloid leukemia patients with resistance to tyrosine kinase inhibitors. <i>Leukemia and Lymphoma</i> , 2019, 60, 200-207.	0.6	11
47	Imatinib mesylate in the management of chemotherapy-induced pulmonary toxicity: a double-edged sword. <i>Acta Oncologica</i> , 2019, 58, 123-124.	0.8	0
48	Tyrosine kinase inhibitors (TKIs) used in the management of chronic myeloid leukaemia are associated with haematologic toxicities"Which TKI is the safest?. <i>British Journal of Clinical Pharmacology</i> , 2019, 85, 2241-2243.	1.1	10
49	Tyrosine Kinase Inhibitor-Associated Platelet Dysfunction: Does This Need to Have a Significant Clinical Impact?. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2019, 25, 107602961986692.	0.7	6
50	The tolerability issue of generic imatinib in patients with chronic myeloid leukemia (Comment on Adi J.) <i>Tj ETQq0 0 0 rgBT /Overlock 10 T</i>	1.7	2
51	Progressive Multifocal Leukoencephalopathy in a Patient with Multiple Myeloma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, e241.	0.2	3
52	New drugs approved for acute myeloid leukaemia in 2018. <i>British Journal of Clinical Pharmacology</i> , 2019, 85, 2689-2693.	1.1	39
53	Tyrosine Kinase Inhibitor Sequencing in Patients with Chronic Myeloid Leukemia. <i>Oncology and Therapy</i> , 2019, 7, 95-100.	1.0	8
54	Is measuring plasma imatinib trough levels still an appropriate way for predicting responses in patients with chronic myeloid leukemia?. <i>Leukemia and Lymphoma</i> , 2019, 60, 2094-2095.	0.6	1

#	ARTICLE	IF	CITATIONS
55	&lt;p&gt;Caplacizumab as an emerging treatment option for acquired thrombotic thrombocytopenic purpura&lt;/p&gt;. Drug Design, Development and Therapy, 2019, Volume 13, 1251-1258.	2.0	38
56	An alternative way â€“ tyrosine kinase inhibitor (TKI) de-escalation â€“ to discontinue TKIs in order to achieve treatment-free remission. Expert Review of Hematology, 2019, 12, 477-480.	1.0	5
57	Coexistence of Hermansky-Pudlak syndrome andJAK2V617F-positive essential thrombocythemia. Ultrastructural Pathology, 2019, 43, 94-98.	0.4	0
58	The Outcomes of Chronic Myeloid Leukemia Patients With Molecular Warning Responses During Imatinib Treatment According to the European LeukemiaNet 2013 Recommendations. Clinical Lymphoma, Myeloma and Leukemia, 2019, 19, e377-e384.	0.2	3
59	PB1929 POTENTIAL DRUG-DRUG INTERACTIONS AMONG PATIENTS WITH CHRONIC MYELOID LEUKEMIA UNDER TYROSINE KINASE INHIBITOR THERAPY WITH IMATINIB. HemaSphere, 2019, 3, 877.	1.2	1
60	Management of Major Surgical Procedures in Patients with Hemophilia: A Single-Center Experience of 49 Procedures. Blood, 2019, 134, 4933-4933.	0.6	0
61	The Real-Life Data on the Outcome of Hepatitis B Infection in Patients with B-Cell Lymphoproliferative Neoplasms Treated with Ibrutinib. Blood, 2019, 134, 4316-4316.	0.6	1
62	The issue of financial toxicity in the management of chronic myeloid leukemia with blast crisis. Journal of Medical Economics, 2018, 21, 709-711.	1.0	2
63	The impact of <i>BCRâ€ABL1</i> transcript type on tyrosine kinase inhibitor responses and outcomes in patients with chronic myeloid leukemia. Cancer, 2018, 124, 3806-3818.	2.0	23
64	Dasatinibâ€nduced pulmonary arterial hypertension. British Journal of Clinical Pharmacology, 2018, 84, 835-845.	1.1	48
65	Comment and response to: the significance of early warning in chronic myeloid leukemia. Expert Review of Hematology, 2018, 11, 267-268.	1.0	0
66	Third-line treatment with second-generation tyrosine kinase inhibitors (dasatinib or nilotinib) in patients with chronic myeloid leukemia after two prior TKIs: real-life data on a single center experience along with the review of the literature. Hematology, 2018, 23, 212-220.	0.7	20
67	Further augmentation of molecular responses with dasatinib therapy in chronic myeloid leukemia patients who gained major molecular response under imatinib. International Journal of Clinical Oncology, 2018, 23, 400-401.	1.0	0
68	Vincristine as an Adjunct to Therapeutic Plasma Exchange for Thrombotic Thrombocytopenic Purpura: A Single Institution Experience. Balkan Medical Journal, 2018, 35, 417-421.	0.3	4
69	Does switching to a second-generation tyrosine kinase inhibitor or increasing imatinib dose have long-term benefits in chronic myeloid leukemia patients with suboptimal responses under upfront standard-dose of imatinib?. Leukemia Research, 2018, 74, 55-56.	0.4	2
70	Starting with a lower daily dose of dasatinib in patients with chronic myeloid leukemia in chronic phase: Less is more, or is it?. Cancer, 2018, 124, 4260-4261.	2.0	1
71	Evolving treatment strategies in CML â€“ moving from early and deep molecular responses to TKI discontinuation and treatmentâ€free remission: is there a need for longerâ€term trial outcomes?. British Journal of Clinical Pharmacology, 2018, 84, 1635-1638.	1.1	10
72	Cytopenia in adult brucellosis patients. Indian Journal of Medical Research, 2018, 147, 73.	0.4	12

#	ARTICLE	IF	CITATIONS
73	Do all patients with chronic myeloid leukemia need to receive interferon during pregnancy?. <i>Leukemia and Lymphoma</i> , 2017, 58, 2019-2020.	0.6	1
74	Upfront nilotinib therapy among patients with chronic myeloid leukemia in chronic phase. <i>Expert Opinion on Pharmacotherapy</i> , 2017, 18, 325-326.	0.9	0
75	Additional chromosomal abnormalities at diagnosis or during tyrosine kinase inhibitor therapy in patients with chronic myeloid leukemia. <i>Leukemia and Lymphoma</i> , 2017, 58, 2516-2517.	0.6	0
76	Tyrosine kinase inhibitor (TKI) therapy for newly-diagnosed patients with chronic myeloid leukemia: focusing on TKI discontinuation due to adverse events "is better always good?". <i>Expert Review of Hematology</i> , 2017, 10, 583-586.	1.0	16
77	Radotinib and its clinical potential in chronic-phase chronic myeloid leukemia patients: an update. <i>Therapeutic Advances in Hematology</i> , 2017, 8, 237-243.	1.1	26
78	Vascular Adverse Events During Long-term Nilotinib Therapy in Patients With Chronic Myeloid Leukemia. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2017, 17, e63-e64.	0.2	0
79	Outcomes of Chronic Myeloid Leukemia Patients With Early Molecular Response at 3 and 6 Months: A Comparative Analysis of Generic Imatinib and Glivec. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2017, 17, 804-811.	0.2	20
80	Midostaurin in FLT3-Mutated Acute Myeloid Leukemia. <i>New England Journal of Medicine</i> , 2017, 377, 1901-1903.	13.9	32
81	Clinical Outcomes Related to the Use of Bendamustine Therapy for Multiple Myeloma Patients Relapsed-Refractory to IMiDs and Proteasome Inhibitors. <i>Turkish Journal of Haematology</i> , 2017, 34, 233-238.	0.2	3
82	Retrospective Evaluation of Hairy Cell Leukemia Patients Treated with Three Different First-Line Treatment Modalities in the Last Two Decades: A Single-Center Experience. <i>Turkish Journal of Haematology</i> , 2017, 34, 291-299.	0.2	7
83	The Management of Chronic Myeloid Leukaemia (CML) Patients with Refractory Disease " Focusing on the Opinions of CML-treating Physicians. <i>European Oncology and Haematology</i> , 2017, 13, 15.	0.0	0
84	The Changing Epidemiology of Bloodstream Infections and Resistance in Hematopoietic Stem Cell Transplantation Recipients. <i>Turkish Journal of Haematology</i> , 2016, 33, 216-222.	0.2	14
85	Dasatinib for the treatment of chronic myeloid leukemia: patient selection and special considerations. <i>Drug Design, Development and Therapy</i> , 2016, Volume 10, 3355-3361.	2.0	32
86	Adverse events of tyrosine kinase inhibitors and their impact on quality of life in patients with chronic myeloid leukemia. <i>Expert Review of Quality of Life in Cancer Care</i> , 2016, 1, 353-359.	0.6	13
87	Second-Line Nilotinib Treatment in Patients With Chronic Myeloid Leukemia in a Developing Country. <i>Clinical Therapeutics</i> , 2016, 38, 680-681.	1.1	0
88	Treatment of patients with immune thrombocytopenia admitted to the emergency room. <i>International Journal of Hematology</i> , 2016, 104, 216-222.	0.7	7
89	Bortezomib therapy in patients with relapsed/refractory acquired thrombotic thrombocytopenic purpura. <i>Annals of Hematology</i> , 2016, 95, 1751-1756.	0.8	44
90	Co-administration of cyclosporine A and imatinib among patients with Philadelphia chromosome-positive leukemias in the post-transplant setting. <i>European Journal of Clinical Pharmacology</i> , 2016, 72, 1537-1538.	0.8	0

#	ARTICLE	IF	CITATIONS
91	Critical appraisal of European LeukemiaNet (ELN) 2013 recommendations for the management of chronic myeloid leukemia: is it early for a warning?. <i>Expert Review of Hematology</i> , 2016, 9, 919-921.	1.0	8
92	Congenital Dyserythropoietic Anemia Type 1: Report of One Patient and Analysis of Previously Reported Patients Treated with Interferon Alpha. <i>Indian Journal of Hematology and Blood Transfusion</i> , 2016, 32, 272-277.	0.3	2
93	Imatinib reduces bone marrow fibrosis and overwhelms the adverse prognostic impact of reticulin formation in patients with chronic myeloid leukaemia. <i>Journal of Clinical Pathology</i> , 2016, 69, 810-816.	1.0	5
94	Pleural tuberculosis in a patient with untreated type 1 Gaucher disease. <i>Journal of Infection and Chemotherapy</i> , 2016, 22, 53-57.	0.8	3
95	Generic imatinib in the treatment of chronic myeloid leukemia: CerrahpaÅYa experience. <i>Journal of Oncology Pharmacy Practice</i> , 2016, 22, 382-384.	0.5	3
96	Comparison of International Prognostic Index and NCCN-IPI in 324 patients with <i>de novo</i> diffuse large B-cell lymphoma: a multi-center retrospective analysis. <i>Leukemia and Lymphoma</i> , 2016, 57, 1211-1214.	0.6	6
97	Real-Life Data and a Single Center Experience on the Efficacy and Toxicity Profile of Imatinib in the Treatment of Elderly Patients with Chronic Myeloid Leukemia. <i>Blood</i> , 2016, 128, 1905-1905.	0.6	0
98	Secondary Infections in Febrile Neutropenia in Hematological Malignancies: More Than Another Febrile Neutropenic Episode. <i>Turkish Journal of Haematology</i> , 2015, 32, 243-250.	0.2	9
99	Relapse after allogeneic hematopoietic stem cell transplant in patients with chronic myeloid leukemia: tyrosine kinase inhibitors, donor lymphocyte infusions or both?. <i>Leukemia and Lymphoma</i> , 2015, 56, 2995-2996.	0.6	4
100	Radotinib in the treatment of chronic phase chronic myeloid leukemia patients. <i>Haematologica</i> , 2015, 100, e39-e39.	1.7	7
101	Treatment and Outcome of Primary and Secondary Thrombotic Microangiopathies. <i>American Journal of Nephrology</i> , 2015, 41, 427-428.	1.4	5
102	Carfilzomib in Relapsed/Refractory Multiple Myeloma, Single Center Experience. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2015, 15, e306-e307.	0.2	0
103	IgD Multiple Myeloma, Descriptive Report of Eight Cases, Single Centre Experience. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2015, 15, e313.	0.2	1
104	The current situation and future aspects of cost-effectiveness in chronic myeloid leukemia treatment. <i>Leukemia and Lymphoma</i> , 2015, 56, 1554-1555.	0.6	2
105	The efficacy and tolerability issue of generics of imatinib in the treatment of chronic myeloid leukemia: do generics really jeopardize patient safety?. <i>Leukemia and Lymphoma</i> , 2015, 56, 1182-1183.	0.6	3
106	Postoperative thrombotic thrombocytopenic purpura. <i>Surgery Today</i> , 2015, 45, 8-16.	0.7	14
107	Real-Life Data and a Single Center Experience on Dasatinib-Induced Pulmonary Arterial Hypertension in Patients with Philadelphia Chromosome-Positive Leukemias. <i>Blood</i> , 2015, 126, 4037-4037.	0.6	3
108	The Treatment of Chronic Myeloid Leukaemia (CML) in the Era of Tyrosine Kinase Inhibitors â€“ What is New in the Battle of CML?. <i>European Oncology and Haematology</i> , 2015, 11, 30.	0.0	2



#	ARTICLE	IF	CITATIONS
109	Acute colitis presenting with hematochezia in a patient with chronic myeloid leukemia during dasatinib therapy. Turkish Journal of Gastroenterology, 2015, 25, 233-233.	0.4	7
110	Second primary malignancies in chronic myeloid leukemia patients. Journal of Cancer Research and Therapeutics, 2015, 11, 1042.	0.3	0
111	Can Positron Emission Tomography and Computed Tomography Be a Substitute for Bone Marrow Biopsy in Detection of Bone Marrow Involvement in Patients with Hodgkinâ€™s or Non-Hodgkinâ€™s Lymphoma?. Turkish Journal of Haematology, 2015, 32, 213-9.	0.2	3
112	Imatinib Mesylate Reduces Bone Marrow Fibrosis and Overwhelms the Adverse Prognostic Impact of Reticulin Formation in Patients with Chronic Myeloid Leukemia. Blood, 2015, 126, 2783-2783.	0.6	1
113	Posttransplant Secondary Neoplasms: A Single Center Experience. Blood, 2015, 126, 5485-5485.	0.6	0
114	Haemophilic Arthropathy Is a Risk Factor for Reduced Bone Mineral Density and Vitamin D Deficiency. Blood, 2015, 126, 4685-4685.	0.6	0
115	New CNV Regions Identified in ITP Provide Evidence for Genetic Predisposition. Blood, 2015, 126, 77-77.	0.6	0
116	The Role of Nitric Oxide in Doxorubicin-Induced Cardiotoxicity: Experimental Study. Turkish Journal of Haematology, 2014, 31, 68-74.	0.2	27
117	Bone-Specific Alkaline Phosphatase Levels among Patients with Multiple Myeloma Receiving Various Therapy Options. Turkish Journal of Haematology, 2014, 31, 374-380.	0.2	3
118	Generics in chronic myeloid leukemia: current arguments for and against and the established evidence. Expert Review of Hematology, 2014, 7, 697-699.	1.0	18
119	Spondylodiscitis: evaluation of patients in a tertiary hospital. Journal of Infection in Developing Countries, 2014, 8, 1272-1276.	0.5	26
120	Chronic myeloid leukemia patients who develop grade I/II pleural effusion under second-line dasatinib have better responses and outcomes than patients without pleural effusion. Leukemia Research, 2014, 38, 781-787.	0.4	33
121	Bone marrow transplantation for Behcet's disease: a case report and systematic review of the literature. Rheumatology, 2014, 53, 1136-1141.	0.9	37
122	The efficacy of generic formulations of imatinib mesylate in the treatment of chronic myeloid leukemia. Leukemia and Lymphoma, 2014, 55, 2935-2937.	0.6	14
123	First line treatment of chronic phase chronic myeloid leukaemia patients with the generic formulations of imatinib mesylate. British Journal of Haematology, 2014, 167, 139-141.	1.2	17
124	Two Cases of Autoimmune Hemolytic Anemia Secondary to Brucellosis: A Review of Hemolytic Disorders in Patients with Brucellosis. Internal Medicine, 2014, 53, 1153-1158.	0.3	16
125	The Prognostic Value of Serum APRIL Levels in Patients with Chronic Lymphocytic Leukemia. Blood, 2014, 124, 5648-5648.	0.6	0
126	Successful Management of Chronic Refractory Immune Thrombocytopenia with Laparoscopic Splenectomy in a Patient with Acute Promyelocytic Leukemia. Indian Journal of Hematology and Blood Transfusion, 2013, 29, 173-177.	0.3	2



#	ARTICLE	IF	CITATIONS
127	Brucellar pericarditis: a report of four cases and review of the literature. <i>International Journal of Infectious Diseases</i> , 2013, 17, e428-e432.	1.5	16
128	Turkish Chronic Myeloid Leukemia Study: Retrospective Sectional Analysis of CML Patients. <i>Turkish Journal of Haematology</i> , 2013, 30, 351-358.	0.2	14
129	B-Cell Chronic Lymphocytic Leukemia and Colon Adenocarcinoma in the Same Mesenteric Lymph Node. <i>Turkish Journal of Haematology</i> , 2013, 30, 98-99.	0.2	1
130	Acute Acalculous Cholecystitis due to Viral Hepatitis A. <i>Case Reports in Infectious Diseases</i> , 2013, 2013, 1-4.	0.2	17
131	Detailed Analysis of Diffuse Large B Cell Lymphoma Patients: A Single-Center, Retrospective Study. <i>ISRN Hematology</i> , 2013, 2013, 1-9.	1.6	8
132	Cyclosporin <sc>A</sc> therapy on idiopathic thrombotic thrombocytopenic purpura in the relapse setting: two case reports and a review of the literature. <i>Transfusion</i> , 2013, 53, 1586-1593.	0.8	14
133	Interstitial Pneumonitis in a Patient with Chronic Myeloid Leukemia. <i>Turkish Journal of Haematology</i> , 2013, 30, 435-436.	0.2	2
134	Next-Generation Sequencing Of The BCR-ABL1 Kinase Domain May Be Beneficial In Decision Making Among Chronic Myeloid Leukemia Patients With Tyrosine Kinase Inhibitor Resistance. <i>Blood</i> , 2013, 122, 384-384.	0.6	1
135	Interstitial pneumonitis in a patient with chronic myeloid leukemia. <i>Turkish Journal of Haematology</i> , 2013, 30, 435-6.	0.2	2
136	Interstitial Pneumonitis in a Patient with Chronic Myeloid Leukemia. <i>Turkish Journal of Haematology</i> , 2013, 30, 435-436.	0.2	2
137	The Association Between JAK2V617F Mutation and Bone Marrow Fibrosis at Diagnosis in Patients with Philadelphia-Negative Chronic Myeloproliferative Neoplasms. <i>Turkish Journal of Haematology</i> , 2012, 29, 242-247.	0.2	0
138	Hypereosinophilic Syndrome Associated with Simultaneous Intracardiac Thrombi, Cerebral Thromboembolism and Pulmonary Embolism. <i>Internal Medicine</i> , 2012, 51, 309-313.	0.3	7
139	Breast schwannoma in a patient with diffuse large B-cell lymphoma: a case report. <i>Journal of Medical Case Reports</i> , 2012, 6, 423.	0.4	2
140	Thrombotic Thrombocytopenic Purpura After Prophylactic Cefuroxime Axetil Administered in Relation to a Liposuction Procedure. <i>Aesthetic Plastic Surgery</i> , 2012, 36, 464-467.	0.5	7
141	Intracranial extramedullary hematopoiesis in patients with thalassemia: a case report and review of the literature. <i>Transfusion</i> , 2012, 52, 1715-1720.	0.8	20
142	Chronic lymphocytic leukemia developing in a patient with Janus kinase 2 V617F mutation positive myeloproliferative neoplasm. <i>Annals of Hematology</i> , 2012, 91, 305-306.	0.8	4
143	Essential Thrombocythemia and Multiple Myeloma: Two Rare Diseases in One Patient. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2011, 11, 442-445.	0.2	12
144	Intracranial mass in a patient with thalassaemia major. <i>British Journal of Haematology</i> , 2011, 152, 126-126.	1.2	2

#	ARTICLE	IF	CITATIONS
145	Chronic myeloid leukemia patients with F317L BCR-ABL kinase domain mutation are resistant to dasatinib: Is that true for all the patients?. <i>Leukemia Research</i> , 2011, 35, e145-e146.	0.4	3
146	Variant Philadelphia translocations with different breakpoints in six chronic myeloid leukemia patients. <i>Turkish Journal of Haematology</i> , 2011, 28, 186-192.	0.2	4
147	Primary Gastrointestinal Diffuse Large B Cell Lymphoma Presenting with Cold Agglutinin Disease. <i>Case Reports in Gastroenterology</i> , 2011, 5, 262-266.	0.3	9
148	Synchronous Detection of Hairy Cell Leukemia and HIV-Negative Kaposi's Sarcoma of the Lymph Node: A Diagnostic Challenge and a Rare Coincidence. <i>Case Reports in Oncology</i> , 2011, 4, 439-444.	0.3	3
149	Pleural and pericardial effusions in chronic myeloid leukemia patients receiving low-dose dasatinib therapy. <i>Haematologica</i> , 2011, 96, e15-e15.	1.7	25
150	ABL gene kinase domain mutation scanning by denaturing high performance liquid chromatography sequencing method. <i>Turkish Journal of Haematology</i> , 2011, 28, 97-102.	0.2	4
151	Multidrug Resistance Gene (MDR1) C3435T Polymorphism and Imatinib Response in Patients with Chronic Myeloid Leukemia. <i>Blood</i> , 2011, 118, 1692-1692.	0.6	3
152	Ten-Year Follow-up Data of Diffuse Large B-Cell Lymphoma Patients: Single Center Experience. <i>Blood</i> , 2011, 118, 5223-5223.	0.6	0
153	CLLU1 Gene Expression Level As a Prognostic Parameter in Patients with Chronic Lymphocytic Leukemia. <i>Blood</i> , 2011, 118, 4603-4603.	0.6	0
154	Imatinib for Chronic Myeloid Leukemia Patients: A Single Institution Experience. <i>Blood</i> , 2011, 118, 4429-4429.	0.6	0
155	Sarcoidosis mimicking lymphoma on positron emission tomography-computed tomography in two patients treated for lymphoma: two case reports. <i>Journal of Medical Case Reports</i> , 2009, 3, 7306.	0.4	8
156	Cytogenetic Clonal Evolution in Patients with Chronic Myeloid Leukemia. <i>Biotechnology and Biotechnological Equipment</i> , 2009, 23, 1515-1520.	0.5	3
157	Primary Cutaneous Immunocytoma/Marginal Zone B-Cell Lymphoma: A Case with Unusual Course. <i>American Journal of Dermatopathology</i> , 2004, 26, 119-122.	0.3	9
158	Retrospective evaluation of hairy cell leukemia patients treated with 3 different first-line treatment modalities in the last two decades: a single center experience. <i>Turkish Journal of Haematology</i> , 0, .	0.2	0
159	Treatment Responses, Toxicity, and Survival in Patients with Classical Hodgkin Lymphoma Aged $\geq 50$ Years: A Single-Center Experience Over Two Decades. <i>Cancer Management and Research</i> , 0, Volume 14, 1911-1921.	0.9	0